Masoud Azodi, MD
Emeritus FacultyDownloadHi-Res Photo
Cards
Contact Info
Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520-8063
United States
About
Copy Link
Titles
Emeritus Faculty
Biography
Dr. Azodi completed his undergraduate, graduate, medical school and Ob/Gyn residency training in Ohio. He then completed his fellowship in Gynecologic Oncology at Yale School of Medicine (YSM) in 1996.
Last Updated on January 16, 2026.
Education & Training
- Fellowship
- Yale University School of Medicine (1999)
- Residency
- Aultman Hospital/Neoucom (1996)
- MD
- Wright State University (1992)
Research
Copy Link
Overview
Please see PubMed for publications.
Medical Research Interests
Biomarkers, Pharmacological; Cerclage, Cervical; Early Detection of Cancer; Fertility Preservation; Hereditary Breast and Ovarian Cancer Syndrome; Laparoscopy; Medical Oncology; Sarcoma, Endometrial Stromal
ORCID
0000-0002-0570-8089
Research at a Glance
Yale Co-Authors
Frequent collaborators of Masoud Azodi's published research.
Publications Timeline
A big-picture view of Masoud Azodi's research output by year.
Research Interests
Research topics Masoud Azodi is interested in exploring.
Alessandro Santin, MD
Pei Hui, PhD, MD
Gloria Huang, MD, FACOG
Mitchell Clark, MD, MPH
Stefania Bellone, PhD
Elena Ratner, MD, MBA
147Publications
5,879Citations
Laparoscopy
Cerclage, Cervical
Sarcoma, Endometrial Stromal
Fertility Preservation
Medical Oncology
Publications
2026
Efficacy of laparoscopic-assisted transversus abdominus plane (LA-TAP) block for minimally invasive gynecologic surgeries (MIGS): A randomized controlled trial
Seifi F, Jiang J, White R, Eaton D, Delis P, Wilcox A, Murphy C, Lundsberg L, Azodi M, Tseng L, Li J. Efficacy of laparoscopic-assisted transversus abdominus plane (LA-TAP) block for minimally invasive gynecologic surgeries (MIGS): A randomized controlled trial. Journal Of Minimally Invasive Gynecology 2026 PMID: 41654083, DOI: 10.1016/j.jmig.2026.02.005.Peer-Reviewed Original ResearchCitationsConceptsMinimally invasive gynecologic surgeryPost-anesthesia care unitPost-anesthesia care unit dischargeWorst painRandomized Controlled TrialsTransversus abdominus planeGynecologic surgeryAcademic healthcare systemIncidence of nausea or vomitingCumulative opioid useEarly postoperative painNausea or vomitingHospital sitesPatient reportsHealthcare systemOutcome assessorsPain regimenPain scoresSecondary outcomesPostoperative painOpioid usePrimary outcomeCumulative usePlain bupivacaineLocal infiltrationThe multidisciplinary management of a patient with infected iliocaval stents and uterine cancer invasion
Said S, Gu E, Li A, Loh S, Mojibian H, Azodi M, Chaar C. The multidisciplinary management of a patient with infected iliocaval stents and uterine cancer invasion. Journal Of Vascular Surgery Cases And Innovative Techniques 2026, 12: 102128. PMID: 41674915, PMCID: PMC12886536, DOI: 10.1016/j.jvscit.2026.102128.Peer-Reviewed Original ResearchThis study investigates multidisciplinary management of infected iliocaval stents in uterine cancer, showing surgical resection controls infection and enables oncologic treatment resumption despite high complication risks.
2025
Association of Platinum-Based Chemotherapy with Survival in Ovarian Carcinosarcoma: A Retrospective Two-Center Cohort Study
Abozenah Y, Erfani H, Haunschild C, Upadhyay A, Greenman M, McNamara B, Papatla K, Clark M, Dottino P, Azodi M, Santin A, Ratner E, Litkouhi B, English D, Altwerger G. Association of Platinum-Based Chemotherapy with Survival in Ovarian Carcinosarcoma: A Retrospective Two-Center Cohort Study. International Journal Of Gynecological Cancer 2025, 104440. PMID: 41535186, DOI: 10.1016/j.ijgc.2025.104440.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPlatinum-based chemotherapyPlatinum-based groupNon-platinum-based regimensOvarian carcinosarcomaCytoreductive surgeryOverall survivalRetrospective two-center cohort studyStage III to IV diseaseAdjuvant platinum-based chemotherapyMalignant mixed Mullerian tumorPlatinum-based chemotherapy regimensCox proportional hazards regression model analysisKaplan-Meier survival curvesMedian overall survivalMixed mullerian tumorsOptimal cytoreductive surgeryTwo-center cohort studyStandard chemotherapy regimenAdvanced-stage diseaseLog-rank testRetrospective chart reviewFirst-line approachYale-New Haven HospitalMulti-institutional studyNon-inferiority designA PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.Peer-Reviewed Original ResearchAdverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case
Abozenah Y, McNamara B, Greenman M, Daigle E, Mikhaiel J, DiCapua D, Kwan J, Azodi M, Altwerger G. Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case. Gynecologic Oncology Reports 2025, 61: 101950. PMID: 41169950, PMCID: PMC12570088, DOI: 10.1016/j.gore.2025.101950.Peer-Reviewed Original ResearchCitationsConceptsLife-threatening complicationsMyasthenia gravisImmune checkpoint inhibitor (ICI)-associated myocarditisComplication of ICI therapyPositive acetylcholine receptor antibodyHigh-dose steroidsTreated with carboplatinEndometrial cancer casesAcetylcholine receptor antibodiesDiagnosis of myocarditisElevated creatine kinaseCritical care managementICI therapyElevated troponinBilateral ptosisEndometrial adenocarcinomaReceptor antibodiesCardiac symptomsTherapeutic challengeMultidisciplinary managementRespiratory compromiseCardiac MRIAdverse eventsCancer casesDostarlimabIn vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma
Greenman M, Hartwich T, Demirkiran C, Bellone S, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. In vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma. Gynecologic Oncology 2025, 200: 318. DOI: 10.1016/j.ygyno.2025.04.452.Peer-Reviewed Original ResearchDatopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma
Greenman M, Demirkiran C, Bellone S, Ettorre V, Hartwich T, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. Datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma. Gynecologic Oncology 2025, 200: 204. DOI: 10.1016/j.ygyno.2025.04.263.Peer-Reviewed Original ResearchRole of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers
Greenman M, Demirkiran C, McNamara B, Altwerger G, Ratner E, Santin A, Papatla K, Dottino P, Azodi M, Schwartz P, Clark M. Role of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers. Gynecologic Oncology 2025, 200: 239-240. DOI: 10.1016/j.ygyno.2025.04.320.Peer-Reviewed Original ResearchRetrospective analysis of lenvatinib and pembrolizumab in endometrial cancer: Efficacy by tumor characteristics, platinum status and lenvatinib dose
Abozenah Y, Dzienny A, Yamartino K, Pan E, Vlamis C, Azodi M, Ratner E, Santin A, Clark M, Papatla K, Schwartz P, Altwerger G. Retrospective analysis of lenvatinib and pembrolizumab in endometrial cancer: Efficacy by tumor characteristics, platinum status and lenvatinib dose. Gynecologic Oncology 2025, 200: 202. DOI: 10.1016/j.ygyno.2025.04.260.Peer-Reviewed Original ResearchFertility preserving, uterine sparing approach to a uterine extragonadal yolk sac tumor
Greenman M, McNamara B, Ettorre V, Buza N, Azodi M. Fertility preserving, uterine sparing approach to a uterine extragonadal yolk sac tumor. Gynecologic Oncology Reports 2025, 59: 101778. PMID: 40585380, PMCID: PMC12205314, DOI: 10.1016/j.gore.2025.101778.Peer-Reviewed Original ResearchConceptsExtragonadal yolk sac tumorYolk sac tumorSac tumorUterine preservationSpontaneously conceived pregnanciesFertility preservation strategiesYoung womenDegenerating fibroidsNegative marginsWedge resectionSurgical approachStaging procedureTreatment optionsTumorCompleted childbearingRecurrencePatientsWomenReproductive goalsObjective treatmentTreatmentHysterectomyFibroidsMyometriumChemotherapy
News & Links
Copy Link
Media
News
- May 09, 2025
16 Yale Ob/Gyn Physicians Named "Top Doctors" for 2025
- November 07, 2024
Yale Ob/Gyn Faculty Present the Latest in Gynecologic Oncology at Memorial Conference
- May 02, 2024
15 Yale Ob/Gyn Physicians Named "Top Doctors" For 2024
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
Get In Touch
Copy Link
Contacts
Mailing Address
Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520-8063
United States
Administrative Support
Locations
Yale Obstetrics, Gynecology & Reproductive Sciences
Academic Office
Farnam Memorial Building
310 Cedar Street, Wing Gynecologic Oncology, Fl 3rd, Ste 328E
New Haven, CT 06510
General Information
203.785.4013Fax
203.785.4135